-
In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year.
-
A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer.
-
Using the SEER database, this report examined 1926 patients aged ≥ 70 years who were diagnosed with limited-stage small cell lung cancer between 1988 and 1997.
-
Long-term complications, particularly secondary cancers, were significantly more common in patients receiving whole pelvic radiation (vs brachytherapy alone) for early-stage endometrial cancer.
-
Administrative databases may not give an accurate representation of hospital-acquired pressure ulcer rates and may be inappropriate for use to compare hospitals and determine financial penalties.
-
-
A fixed dose of oral apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding.
-
-
-
For patients with BRCA-associated breast cancer, it had been previously demonstrated that a second breast cancer occurs in approximately one-third of patients by 15 years after diagnosis, and that this risk was reduced significantly by contralateral mastectomy.
